| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Sep 2025 | 2 Sep 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2025 inter alia to consider and approve To discuss and approve the following matters: Discussion on Notice for 38th Annual General Meeting for the Company. Discussion on Director Report of the Company for the Financial Year 2024-2025. Discussion to Fix Date Place and Timing of 38th Annual General Meeting of the Company Discussion on matter related to Loan to Equity shares of the Company. Any other business with the permission of Chairperson. | ||
| Board Meeting | 25 Aug 2025 | 19 Aug 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2025 inter alia to consider and approve 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson. Outcome of Board meeting for Appointment Statutory Auditor and Independent Director (As Per BSE Announcement Dated on: 26/08/2025) Revised outcome of Board Meeting held on 25th August 2025. The earlier revised outcome uploaded has incorrect w.e.f date of appointment of statutory auditor. The correct w.e.f date is 25th August,2025 (As per BSE Announcement Dated on 27/08/2025) | ||
| Board Meeting | 12 Aug 2025 | 5 Aug 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve Intimation of Board Meeting to be held on 12th August 2025. Approval of unaudited financial results for the quarter ended 30/06/2025 Approval of unaudited financial results for the quarter ended 30th June 2025 (As Per BSE Announcement Dated on:12.08.2025) | ||
| Board Meeting | 16 Jul 2025 | 11 Jul 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/07/2025 ,inter alia, to consider and approve 1. To consider and discuss the appointment of a new Executive Director and Chief Financial Officer (CFO) of the Company; 2. To consider and discuss the resignation of the present Chief Financial Officer (CFO) of the Company. 3. Any other business with the permission of chair. Appointment of Ms. Chaitali Kalpataru Shah as a Executive Director and CFO of the Company Outcome of Board Meeting Held on 16th July, 2025 (As Per BSE Announcement Dated on: 16/07/2025) | ||
| Board Meeting | 26 May 2025 | 17 May 2025 |
| Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve 1. Approval of the Audited Financial Results of the Company for the quarter and Yearly ended 31st March 2025; 2. Any other business with the permission of Chairperson. Outcome of Board Meeting for Approval of Audited Financials for the year ended 31st March,2025 (As Per BSE Announcement Dated on :26.05.2025) Audited Financial Results for the year ended 31st March ,2025 (As Per BSE Announcement Dated on :26.05.2025) | ||
| Board Meeting | 21 Jan 2025 | 13 Jan 2025 |
| BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2025 inter alia to consider and approve 1) the Un-Audited Financial Results along with Limited Review Report of the Company for the Quarter ended 31st December 2024. 2) Other routine business with the permission of the Chair. Outcome of Board meeting (As Per BSE Announcement Dated on: 21/01/2025) | ||
| Board Meeting | 12 Nov 2024 | 12 Nov 2024 |
| Submission of Corrigendum to the Notice of EOGM dated 15/10/2024 submitted on 23/10/2024 as per attachment | ||
| Board Meeting | 23 Oct 2024 | 16 Oct 2024 |
| BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results along with Statements of Assets and Liabilities and Cash Flow Statement of the Company for the Quarter and half year ended 30th September 2024. 2) Other routine business with the permission of the Chair. outcome of Board Meeting held on 23rd October 2024 (As Per BSE Announcement Dated on: 23/10/2024) | ||
| Board Meeting | 15 Oct 2024 | 10 Oct 2024 |
| BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2024 inter alia to consider and approve items mentioned in the notice of Board meeting. Outcome of Board Meeting held on 15th October,2024 Approved the acquisition of 5527000 Equity shares of M/s. CNX Corporation Limited (CCL) subject to approval of members of the Company at ensuing Extra Ordinary General Meeting. Revised Outcome of Board Meeting due to clerical mistake in list of allotee. (As Per BSE Announcement dated on 15.10.2024) | ||
| Board Meeting | 27 Sep 2024 | 21 Sep 2024 |
| BACIL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/09/2024 inter alia to consider and approve matters stated in intimation OUTCOME OF BOARD MEETING HELD ON 27TH SEPTEMBER, 2024. (As per BSE Announcement Dated on 27/09/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.